Related Articles for PubMed (Select 18269691)

The protein C pathway: implications for the design of the RESPOND study.

Vangerow B, Shorr AF, Wyncoll D, Janes J, Nelson DR, Reinhart K.

Crit Care. 2007;11 Suppl 5:S4. Review.

PMID: 18269691 [PubMed - indexed for MEDLINE]

Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).

Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J.

Crit Care. 2008;12(2):R45. Epub 2008 Apr 4. Review.

PMID: 18394162 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators.

Chest. 2004 Jun;125(6):2206-16.

PMID: 15189943 [PubMed - indexed for MEDLINE]

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

Crit Care Med. 2004 Nov;32(11):2199-206.

PMID: 15640631 [PubMed - indexed for MEDLINE]

Clinical trials in severe sepsis with drotrecogin alfa (activated).

Laterre PF.

Crit Care. 2007;11 Suppl 5:S5. Review.

PMID: 18269692 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

N Engl J Med. 2005 Sep 29;353(13):1332-41.

PMID: 16192478 [PubMed - indexed for MEDLINE]

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61.

PMID: 17084715 [PubMed - indexed for MEDLINE]

From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).

Short MA, Schlichting D, Qualy RL.

Curr Med Res Opin. 2006 Dec;22(12):2525-40. Review.

PMID: 17265595 [PubMed - indexed for MEDLINE]

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

Surgery. 2007 Apr;141(4):548-61.

PMID: 17431957 [PubMed - indexed for MEDLINE]

10:

International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.

Sashegyi A, Trzaskoma BL, Nelson DR, Williams MD, Macias W.

Curr Med Res Opin. 2006 May;22(5):1001-12.

PMID: 16709322 [PubMed - indexed for MEDLINE]

11:

Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

Barie PS, Hydo LJ, Shou J, Eachempati SR.

Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.

PMID: 16895513 [PubMed - indexed for MEDLINE]

12:

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.

Vincent JL, O'Brien J Jr, Wheeler A, Wittebole X, Garg R, Trzaskoma BL, Sundin DP.

Crit Care. 2006;10(3):R74. Epub 2006 May 9.

PMID: 16684364 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

13:

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

Crit Care Med. 2008 Jan;36(1):14-23.

PMID: 18158435 [PubMed - indexed for MEDLINE]

14:

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.

Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, Johnson G 3rd, Small DS.

Clin Pharmacol Ther. 2002 Oct;72(4):391-402.

PMID: 12386641 [PubMed - indexed for MEDLINE]

15:

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group.

Am J Respir Crit Care Med. 2007 Sep 1;176(5):483-90. Epub 2007 Jun 7.

PMID: 17556722 [PubMed - indexed for MEDLINE]

16:

Drotrecogin alfa (activated): real-life use and outcomes for the UK.

Rowan KM, Welch CA, North E, Harrison DA.

Crit Care. 2008;12(2):R58. Epub 2008 Apr 22.

PMID: 18430215 [PubMed - indexed for MEDLINE]

Related Articles Free article in PMC

17:

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.

Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC.

Crit Care Med. 2004 Nov;32(11):2207-18.

PMID: 15640632 [PubMed - indexed for MEDLINE]

18:

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH.

Health Technol Assess. 2005 Mar;9(11):1-126, iii-iv.

PMID: 15774234 [PubMed - indexed for MEDLINE]

19:

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP.

Pediatrics. 2004 Jan;113(1 Pt 1):7-17.

PMID: 14702440 [PubMed - indexed for MEDLINE]

20:

International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.

Dhainaut JF; INDEPTH Clinical Evaluation Committee.

Curr Med Res Opin. 2008 Apr;24(4):1187-97. Epub 2008 Mar 17.

PMID: 18348744 [PubMed - indexed for MEDLINE]

Recent Activity